Dataset from A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Primary Objective:

To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone
and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c)
change from baseline to Week 30.

Secondary Objective:

To compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio
combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin
treatment) over a 30 week treatment period in participants with type 2 diabetes.

主要研究终点：

比较甘精胰岛素/利司那肽固定比例复方制剂与单用利司那肽、单用甘精胰岛素（均联合二甲双胍治疗）在糖化血红蛋白（HbA1c）从基线至第30周的变化差异。

次要研究终点：

在2型糖尿病受试者中，比较甘精胰岛素/利司那肽固定比例复方制剂（FRC）与单用甘精胰岛素、单用利司那肽（均联合二甲双胍治疗）在30周治疗周期内的整体有效性与安全性。